Objective: To quantify infusion-flow reduction associated with concomitant use of opicapone in patients receiving LDp/CDp infusion and to describe dyskinesia and cutaneous tolerability outcomes during follow-up.
Background: Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion is an advanced therapy for Parkinson’s disease, frequently complicated by infusion-site reactions which may be related to infusion volume and flow. Opicapone co-administration may permit lower infusion flow while maintaining tolerability and effectiveness.
Method: We conducted a real-world case series of 12 patients treated with LDp/CDp infusion and concomitant opicapone. Total infusion flow was assessed within-subject by comparing initial theoretical/starting flow with the adjusted flow after titration. The primary endpoint was change in flow, evaluated using a two-sided Wilcoxon signed-rank test (paired t-test as sensitivity analysis). Follow-up outcomes included dyskinesias (0–3) and cutaneous adverse events/nodules (0–3), summarized descriptively. Exploratory associations between percentage flow reduction and follow-up outcomes were assessed using Spearman’s rank correlation.
Results: Concomitant opicapone was associated with an overall weighted infusion-flow reduction of 35.54% (130.56 to 84.16). The pre–post reduction in flow was statistically significant (Wilcoxon p = 0.00098; paired t-test p = 0.0020). During follow-up, cutaneous adverse events/nodules were observed in 6/12 patients (50.0%): mild 41.7%, moderate 0%, severe 8.3%. Dyskinesias occurred in 6/12 patients (50.0%): mild 41.7%, moderate 8.3%, severe 0%. Percentage flow reduction was not significantly correlated with cutaneous adverse event/nodule severity (Spearman ρ = −0.35, p = 0.259) or dyskinesia severity (Spearman ρ = 0.086, p = 0.791).
Conclusion: In this small cohort, opicapone co-administration enabled a statistically significant reduction in LDp/CDp infusion flow. Cutaneous adverse events/nodules and dyskinesias were generally mild during follow-up, and no clear relationship was observed between the magnitude of flow reduction and safety outcomes. Larger prospective studies are warranted.
To cite this abstract in AMA style:
G. Tabar Comellas, N. Lopez Ariztegui, M. Morales Casado. Opicapone Co-administration Allows Significant Flow Reduction in Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: A Real-World Case Series [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/opicapone-co-administration-allows-significant-flow-reduction-in-continuous-subcutaneous-foslevodopa-foscarbidopa-infusion-a-real-world-case-series/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/opicapone-co-administration-allows-significant-flow-reduction-in-continuous-subcutaneous-foslevodopa-foscarbidopa-infusion-a-real-world-case-series/